Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TransGen Biotech is a China-based life science tools and reagent company focused on the research, development, manufacturing, and sale of molecular biology, cell biology, protein research, and in vitro diagnostic reagents. The company sells a broad catalog of research products including PCR and qPCR reagents, reverse transcription reagents, cloning vectors, nucleic acid purification kits, NGS library preparation products, serum-free media, cell biology reagents, antibodies, ELISA tools, and related instruments and consumables. It operates internal platforms spanning upstream protein raw materials, reagent development, and downstream diagnostic reagent R&D, and serves research, clinical laboratory, and biopharma quality-control workflows. TransGen appears to be a commercially operating private company rather than a therapeutic drug developer, with revenues generated from product sales rather than a drug pipeline. The company is headquartered in Beijing and has built a domestic distribution network along with international distributors.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on TransGen Biotech.